drugset / Trial / NCT00718419

A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma

NCT00718419

Phase 2 Completed 56 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

To determine whether further study of single-agent enzastaurin is warranted in patients with previously treated Waldenstrom's Macroglobulinemia or Multiple Myeloma based on response.

Timeline

Start
2008-07
Primary completion
2010-09
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject enzastaurin Small molecule 250 mg Oral